The scientist behind the analysis.

Dr. Gregory Newkirk, Ph.D.

I’ve delivered technical due diligence for biotech investment decisions — evaluating whether the science holds up, how defensible the IP is, and where the real risks lie. That work draws on over a decade of hands-on molecular biology research, spanning CRISPR gene editing, nanotechnology, and agricultural biotechnology.

My doctoral research at UC Riverside in the Giraldo Laboratory focused on the intersection of nanotechnology and plant biology, developing novel approaches for delivering biomolecules into plant cells using engineered nanomaterials. That work led to publications in Nature Nanotechnology and ACS Nano, and to a granted U.S. patent — U.S. Patent 11,186,845 B1 — on which I am a named inventor.

Before my doctoral work, I served as Senior Research Associate at Cibus, leading next-generation sequencing and CRISPR initiatives. I then joined BASF as Scientist III, leading the Host Strain Engineering team building CRISPR-based tools for agricultural biotechnology.

I completed formal patent training through the Casimir Jones Life Sciences Patent Academy. That training, combined with the experience of filing my own patent, means I understand IP not as an abstraction but from the inventor’s perspective. I founded Priori Intelligence to bring that combination — real scientific depth plus genuine IP literacy — to investors and founders who need more than keyword searches and boilerplate reports.

AI-accelerated. Scientist-validated. Never the other way around.

Every analysis is AI-accelerated but scientist-validated. I use modern research tools for speed and scale, then apply the scientific judgment that only comes from years at the bench. Investors need to decide fast; the goal is a rigorous, honest technical read in days, not weeks — without the generic boilerplate that passes for due diligence elsewhere.